Topics:
Breast Cancer • Medical Oncology
If a patient is unable to tolerate one CDK 4/6 inhibitor, do you switch to a different one?
For example, a patient has had multiple dose reductions for neutropenia and required an admission for infection while on palbociclib. Would you switch to abemaciclib?
Answer from: Medical Oncologist at Community Practice
There are currently no data about switching from one CDK 4/6 inhibitor to another. The current recommendations for palbociclib with grade 3 neutropenia and infection are to hold palbociclib until recovery to grade 2 or less and then dose reduce. It sounds as though this patient has required multiple...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I agree. I have had success switching from palbociclib to abemaciclib for patients with neutropenia, and from one CDK4/6 inhibitor to another for a patient with cutaneous toxicity.
Answer from: Medical Oncologist at Community Practice
Yes